. 2023 May 16;14:1144422. doi: 10.3389/fendo.2023.1144422

Table 1.

Study characteristics of the included 16 RCTs.

	Study	Design	Disease	Numbers of participants	Gender (F/M)	Interventions details	Follow-up (months)
1	Brown VISTA 2015 (12)	VISTA	DME	461	45.5%/54.5%	Aflibercept 2.0mg	24
1	Brown VISTA 2015 (12)	VISTA	DME	461	45.5%/54.5%	Laser photocoagulation	24
2	Brown VIVID 2015 (12)	VIVID	DME	404	38.2%/61.8%	Aflibercept 2.0mg	24
2	Brown VIVID 2015 (12)	VIVID	DME	404	38.2%/61.8%	Laser photocoagulation	24
3	DRCR.net 2015 (13)	Protocol T	CI-DME	660	47%/53%	Aflibercept 2.0mg	12
3	DRCR.net 2015 (13)	Protocol T	CI-DME	660	47%/53%	Ranibizumab 0.3mg	12
4	Wells 2016 (14)	Protocol T	CI-DME	660	47%/53%	Aflibercept 2.0mg	24
4	Wells 2016 (14)	Protocol T	CI-DME	660	47%/53%	Ranibizumab 0.3mg	24
5	Sivaprasad 2017 (15)	CLARITY	PDR	232	33.2%/66.8%	Aflibercept 2.0mg	24
5	Sivaprasad 2017 (15)	CLARITY	PDR	232	33.2%/66.8%	PRP	24
6	Fouda 2017 (16)	RCT	DME	42	NR-no rated	Aflibercept 2.0mg	24
6	Fouda 2017 (16)	RCT	DME	42	NR-no rated	Ranibizumab 0.5mg	24
7	Baker 2019 (17)	RCT	CI-DME	702	38%/62%	Aflibercept 2.0mg	24
7	Baker 2019 (17)	RCT	CI-DME	702	38%/62%	Laser photocoagulation	24
8	Ozsaygili 2019 (18)	RCT	DME	62	43.5%/56.5%	Aflibercept 2.0mg	12
8	Ozsaygili 2019 (18)	RCT	DME	62	43.5%/56.5%	Dexamethasone 0.7mg	12
9	Chen 2020 (19)	VIVID-East	DME	381	49.7%/50.3%	Aflibercept 2.0mg	12
9	Chen 2020 (19)	VIVID-East	DME	381	49.7%/50.3%	Laser photocoagulation	12
10	Chatzirallis 2020 (20)	RCT	DME	112	45.5%/54.5%	Aflibercept 2.0mg	12
10	Chatzirallis 2020 (20)	RCT	DME	112	45.5%/54.5%	Ranibizumab 0.5mg	12
11	Antoszyk 2020 (21)	RCT	PDR	205	44%/56%	Aflibercept 2.0mg	24
11	Antoszyk 2020 (21)	RCT	PDR	205	44%/56%	Vitrectomy with PRP	24
12	Beaulieu 2021 (22)	Protocol V	CI-DME	387	37%/63%	Aflibercept 2.0mg	24
12	Beaulieu 2021 (22)	Protocol V	CI-DME	387	37%/63%	Laser photocoagulation	24
13	Brown KESTREL 2022 (23)	KESTREL	DME	566	37.3%/62.7%	Aflibercept 2.0mg	12
13	Brown KESTREL 2022 (23)	KESTREL	DME	566	37.3%/62.7%	Brolucizumab 6.0 mg	12
14	Brown KITE 2022 (23)	KITE	DME	360	34.7%/65.3%	Aflibercept 2.0mg	12
14	Brown KITE 2022 (23)	KITE	DME	360	34.7%/65.3%	Brolucizumab 6.0 mg	12
15	Wykof YOSEMITE 2022 (24)	YOSEMITE	DME	940	40.2%/59.8%	Aflibercept 2.0mg	12
15	Wykof YOSEMITE 2022 (24)	YOSEMITE	DME	940	40.2%/59.8%	Faricimab 6.0 mg	12
16	Wykof RHINE 2022 (24)	RHINE	DME	951	39.1%/60.9%	Aflibercept 2.0mg	12
16	Wykof RHINE 2022 (24)	RHINE	DME	951	39.1%/60.9%	Faricimab 6.0 mg	12

RCT, randomized controlled trial; F, female; M, male; DME, diabetic macular edema; CI-DME, center-involved diabetic macular edema; PDR, proliferative diabetic retinopathy; PRP, panretinal photocoagulation.